Clinical-stage immuno-oncology company Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported encouraging early response ...

The Alliance for Clinical Trials in Oncology has launched a new clinical trial for adults who need first-line therapy for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The ...

The approval was based on the AMPLIFY trial, which evaluated acalabrutinib alongside venetoclax in adults with previously untreated CLL without del(17p) or TP53 mutation.

Ascentage Pharma will host a Chinese (Mandarin) language investor webcast at 10:00 pm EDT on March 25, 2026 / 10:00 am HKT on March 26, 2026. To access the Chinese language investor event or ...

Rhythm Biosciences is entering a new commercial era, following the first sale of its revolutionary Colostat bowel cancer assay. ... Read More The post Health Check: Rhythm Biosciences is in the groove ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...

February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...

What Is It, and Why Does It Matter? The FDA has approved a new combination treatment for adults with certain cancers of the blood and lymphatic system. The targeted regimen combines Calquence ...

US FDA approves AstraZeneca’s Calquence plus venetoclax as first all-oral, fixed-duration combination for patients with CLL in the 1st-line setting: Cambridge, UK Monday, Februa ...

Chinese biotech Innovent Biologics (HKEX: 01801) has secured approval from China’s National Medical Products Administration ...

Marie Hindee experienced a breakthrough in her 15-year battle with chronic lymphocytic leukemia and small lymphocytic lymphoma after undergoing a cutting-edge therapy at Corewell Health Beaumont ...

FDA cleared acalabrutinib plus venetoclax as the only all-oral, fixed-dose combination option for first-line, treatment-naïve CLL/SLL. Phase 3 AMPLIFY showed superior PFS versus chemoimmunotherapy, ...